Loading clinical trials...
Loading clinical trials...
A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)
Conditions
Interventions
Kedrion IVIG 10%
Locations
21
United States
Benioff Children's Hospital - Mission Bay
San Francisco, California, United States
IMMUNOe Health and Research Centers
Centennial, Colorado, United States
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, United States
Velocity Clinical Research - MedPharmics - Lafayette
Lafayette, Louisiana, United States
Louisiana State University Shreveport
Shreveport, Louisiana, United States
Duke Children's Hospital & Health Center
Durham, North Carolina, United States
Start Date
March 31, 2021
Primary Completion Date
April 30, 2026
Completion Date
October 30, 2026
Last Updated
January 15, 2026
NCT07346859
NCT05236764
NCT05755035
NCT05513586
NCT06955793
NCT04842643
Lead Sponsor
Kedrion S.p.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions